P454 Outcomes of Fecal Microbiota Transplantation for Clostridium difficile Infection in Patients With Inflammatory Bowel Disease
Author insight from Monika Fischer, MD, Indiana University-Purdue University Indianapolis, IN
What’s new here and important for clinicians?
In patients with inflammatory bowel disease (IBD) fecal microbiota transplant (FMT) is highly efficacious to treat recurrent C. difficile infection, albeit, the cure rate with a single FMT was found to be lower (80%) compared to patients without IBD. The overall success rate of FMT ( with 2 or more procedures was 90%. The clinical course of IBD did not change in 34%, and actually improved in half of the patients (49%), but worsened in a small portion of patients. The latter group of patients already had severe, therapy refractory disease course prior to the FMT; the post-FMT worsening in the IBD disease course was likely rather due to the natural course of the disease than consequence of FMT. The procedure was safe with rare adverse effects.
What do patients need to know?
Patients with IBD are commonly diagnosed with with C. difficile infection and it is more challenging to treat with antibiotics than in otherwise healthy counterparts. Recurrent C. difficile infection is highly treatable with stool transplant and few possible side effects. The clinical course of IBD improved in half of the patients after the procedure, was unchanged in 1/3 and only a small portion had worsening IND related symptoms after FMT.
Monika Fischer, MD, Indiana University-Purdue University Indianapolis, IN
Oral 72 Fresh, Frozen, or Lyophilized Fecal Microbiota Transplantation (FMT) for Multiple Recurrent C. difficile Infection (CDI)
Oral 71 C. difficile Associated Risk of Death Score (CARDS): A Novel Risk Score to Predict Mortality Among Hospitalized Patients With C. difficile Infection
P1639 Fecal Microbiota Transplant for Treatment of Refractory C. difficile Colitis: Long-Term Follow-Up of 58 Patients
Media Interview Requests:
To arrange an interview with any ACG experts or abstract authors please contact Jacqueline Gaulin of ACG via email firstname.lastname@example.org or by phone at 301-263-9000.